International Journal of Endocrinology / 2016 / Article / Tab 2

Review Article

Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials

Table 2

Eligible RCTs where myo-inositol and/or D-chiro-inositol have been evaluated for the treatment of PCOS patients undergoing ART.

RefStudy designDurationTreatmentNumber of subjectsInclusion criteriaExclusion criteriaAssessment of the response

[25]Randomized,
controlled
During
ovulation
induction
for ICSI
Treated group:
Myo-Ins 4 g + FA 400 µg/d
Control group:
FA 400 µg/d
Number = 60
Treated: 30
Control: 30
Age: <40 years, PCOS, oligo/amenorrhea,
hyperandrogenism,
hyperandrogenemia,
typical features of ovaries on ultrasound scan
Hyperinsulinemia,
hyperprolactinemia,
hypothyroidism,
androgen excess due to
adrenal hyperplasia or
Cushing syndrome
E2, stimulation (days), FSH IU
Number of retrieved oocytes
Number of MII, number of immature oocytes
Number of embryos grade 1, embryo cleavage rate, fertilization rate
Number of biochemical pregnancies
Number of abortion cancellation rate
Ovarian hyperstimulation syndrome

[26]Double-blind randomized
controlled
12 weeksTreated group:
Myo-Ins 4 g + FA 400 μg/d
Control group:
FA 400 μg/d
Number = 34
Treated: 17
Control: 17
Age: <40 years, PCOS,
oligo/amenorrhea, hyperandrogenism,
hyperandrogenemia,
typical features of ovaries on ultrasound scan
Hypothyroidism,
hyperthyroidism,
diabetes mellitus,
androgen-secreting cancers,
adrenal hyperplasia,
Cushing syndrome
E2, total r-FSH
Number of follicles with a diameter >15 mm
Number of oocytes retrieved
Number of immature oocytes
Number of embryos grade 1
Number of transferred embryos
Number of biochemical pregnancies

[27]Randomized,
controlled
24 weeksTreated group:
Myo-Ins 4 g + FA 400 µg/d
Control group:
metformin 1.5 g/d
Number = 120
Treated: 60
Control: 60
Age: <35 years,
PCOS according to Rotterdam criteria
Hyperprolactinemia, hypothyroidism,
androgen excess,
adrenal hyperplasia or Cushing’s syndrome, tubal defects, semen parameters defects
Restoration of spontaneous ovarian activity by weekly serum P dosage and a transvaginal ultrasound scan documenting the presence of follicular growth or luteal cyst
Number of pregnancies
Abortion rate

[28]Randomized
controlled
8 weeks before r-FSHTreated group:
D-chiro-Ins 300, 600, 1200, and 2400 mg/d
Control group:
placebo
Number = 54
Treated:
4 groups (10–12 pts)
Control: 11
Age: <40 years,
PCOS according to Rotterdam criteria,
undergoing ICSI procedure
Insulin resistance
and/or hyperglycaemia
Total r-FSH, E2, stimulation (days)
Number of oocytes retrieved
Number of cycles cancelled
Number of MII, number of immature oocytes
Number of embryos grade 1

[29]Randomized
controlled
8 weeks before r-FSHTreated group:
Myo-Ins 4 g/d
Control group:
D-chiro-Ins 1.2 g/d
Number = 84
Treated: 43
Control: 41
Age: <40 years,
PCOS according to Rotterdam criteria,
undergoing ICSI procedure
Insulin resistance
and/or hyperglycaemia
Duration of infertility, BMI, PRL, TSH, E2, stimulation (days), FSH
Number of cancelled cycles
Number of retrieved oocytes
Number of MII, number of immature oocytes
Number of embryos grade 1
Number of biochemical/clinical pregnancies
Number of spontaneous abortions

[30]Randomized
controlled
12 weeks before r-FSHTreated group:
Myo-Ins 1.1 g + D-chiro-Ins 27.6 mg/d
Control group:
D-chiro-Ins 1 g/d
Number = 100
Treated: 47
Control: 53
Age: ≤35 years, >35 years
BMI <28 kg/m2, FSH <10 IU/L
PCOS according to Rotterdam 2003 and a normal uterine cavity
Advanced stage (III or IV) endometriosis
Poor responders pts or suffering from premature ovarian failure
Total IU of r-FSH, E2 before hCG injection
Number of MII, number of VG-DEG
Number of embryos grade 1
Number of embryos transferred
Maturation rate and fertilization rate

Myo-Ins, myo-inositol; D-chiro-Ins, D-chiro-inositol; FA, folic acid; PCOS, polycystic ovary syndrome; E2, oestradiol; r-FSH, recombinant follicle stimulating hormone; MII, mature oocytes; VG-DEG, immature oocytes and degenerated oocytes; hCG, Human Chorionic Gonadotropin; ART, assisted reproductive technology.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.